Total Payments
$157,502
2024 Payments
$23,260
Companies
15
Transactions
66
Medicare Patients
4,931
Medicare Billing
$501,530
Payment Breakdown by Category
Consulting$122,656 (77.9%)
Other$20,625 (13.1%)
Food & Beverage$7,486 (4.8%)
Research$5,574 (3.5%)
Travel$1,160 (0.7%)
Education$0.83 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $122,656 | 31 | 77.9% |
| Honoraria | $11,000 | 4 | 7.0% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,625 | 2 | 6.1% |
| Food and Beverage | $7,486 | 20 | 4.8% |
| Unspecified | $5,574 | 2 | 3.5% |
| Travel and Lodging | $1,160 | 6 | 0.7% |
| Education | $0.83 | 1 | 0.0% |
Payments by Type
General
$151,928
64 transactions
Research
$5,574
2 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| OPTOVUE, INC. | $50,023 | 13 | $0 (2021) |
| Amgen Inc. | $41,242 | 21 | $0 (2024) |
| Visionix USA, Inc | $15,000 | 3 | $0 (2024) |
| F. Hoffmann-La Roche AG | $13,699 | 3 | $0 (2022) |
| Genentech USA, Inc. | $13,194 | 8 | $0 (2024) |
| Genentech, Inc. | $10,519 | 5 | $0 (2018) |
| Novartis Pharma AG | $6,988 | 2 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $4,750 | 1 | $0 (2023) |
| TOPCON CORPORATION | $1,500 | 1 | $0 (2021) |
| Regeneron Healthcare Solutions, Inc. | $221.41 | 2 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,260 | 12 | Amgen Inc. ($14,450) |
| 2023 | $13,707 | 5 | Amgen Inc. ($8,915) |
| 2022 | $9,686 | 2 | Visionix USA, Inc ($9,000) |
| 2021 | $38,377 | 11 | OPTOVUE, INC. ($22,000) |
| 2020 | $500.00 | 1 | Amgen Inc. ($500.00) |
| 2019 | $21,208 | 7 | OPTOVUE, INC. ($19,008) |
| 2018 | $31,878 | 13 | OPTOVUE, INC. ($9,000) |
| 2017 | $18,886 | 15 | Amgen Inc. ($7,510) |
All Payment Transactions
66 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 10/09/2024 | Amgen Inc. | PAVBLU (Biological) | Consulting Fee | Cash or cash equivalent | $7,379.87 | General |
| Category: Inflammation | ||||||
| 10/09/2024 | Amgen Inc. | PAVBLU (Biological) | Consulting Fee | Cash or cash equivalent | $1,054.27 | General |
| Category: Inflammation | ||||||
| 10/09/2024 | Amgen Inc. | PAVBLU (Biological) | Travel and Lodging | Cash or cash equivalent | $24.43 | General |
| Category: Inflammation | ||||||
| 08/23/2024 | Visionix USA, Inc | OPTICAL COHERENCE TOMOGRAPHY HOCT-1F (Device) | Food and Beverage | Cash or cash equivalent | $3,000.00 | General |
| Category: Optometry | ||||||
| 06/21/2024 | Amgen Inc. | PAVBLU (Biological) | Consulting Fee | Cash or cash equivalent | $4,915.00 | General |
| Category: Inflammation | ||||||
| 06/21/2024 | Amgen Inc. | PAVBLU (Biological) | Consulting Fee | Cash or cash equivalent | $1,054.27 | General |
| Category: Inflammation | ||||||
| 06/17/2024 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $43.92 | General |
| 05/17/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $16.42 | General |
| 05/17/2024 | Amgen Inc. | — | Food and Beverage | In-kind items and services | $5.24 | General |
| 05/15/2024 | Visionix USA, Inc | OPTICAL COHERENCE TOMOGRAPHY HOCT-1F (Device) | Food and Beverage | Cash or cash equivalent | $3,000.00 | General |
| Category: Optometry | ||||||
| 04/04/2024 | Genentech USA, Inc. | Vabysmo (Drug) | Consulting Fee | Cash or cash equivalent | $2,750.00 | General |
| Category: Immunology and Ophthalmology | ||||||
| 03/19/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $16.55 | General |
| Category: EYE CARE | ||||||
| 11/29/2023 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $41.84 | General |
| Category: OPHTHALMOLOGY | ||||||
| 11/08/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,932.00 | General |
| 11/08/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $983.00 | General |
| 08/09/2023 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,750.00 | General |
| 02/10/2023 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $4,000.00 | General |
| 10/12/2022 | Visionix USA, Inc | AngioVue (Device) | Consulting Fee | Cash or cash equivalent | $9,000.00 | General |
| Category: Optometry | ||||||
| 06/30/2022 | F. Hoffmann-La Roche AG | Lucentis (Biological) | — | In-kind items and services | $685.56 | Research |
| Study: RELATIONSHIP BETWEEN RETINAL FLUID CHARACTERISTICS AND VISION IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A POST HOC ANALYSIS OF HARBOR • Category: Ophthalmology | ||||||
| 12/28/2021 | OPTOVUE, INC. | AngioVue (Device) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Optometry | ||||||
| 11/24/2021 | Amgen Inc. | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 11/22/2021 | TOPCON CORPORATION | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| 10/13/2021 | OPTOVUE, INC. | Solix (Device) | Honoraria | Cash or cash equivalent | $1,000.00 | General |
| Category: Optometry | ||||||
| 10/07/2021 | OPTOVUE, INC. | AngioVue (Device) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Optometry | ||||||
| 09/21/2021 | OPTOVUE, INC. | AngioVue (Device) | Consulting Fee | Cash or cash equivalent | $6,000.00 | General |
| Category: Optometry | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| LUCENTIS DOSING RETREATMENT | F. Hoffmann-La Roche AG | $4,889 | 1 |
| RELATIONSHIP BETWEEN RETINAL FLUID CHARACTERISTICS AND VISION IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION A POST HOC ANALYSIS OF HARBOR | F. Hoffmann-La Roche AG | $685.56 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 842 | 1,639 | $1.1M | $112,615 |
| 2022 | 6 | 1,333 | 2,139 | $1.3M | $127,129 |
| 2021 | 6 | 1,451 | 2,286 | $1.3M | $138,791 |
| 2020 | 7 | 1,305 | 2,055 | $1.1M | $122,995 |
Total Patients
4,931
Total Services
8,119
Medicare Billing
$501,530
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 92014 | Established patient complete exam of visual system | Office | 2023 | 341 | 649 | $541,915 | $67,188 | 12.4% |
| 67028 | Injection of drug into eye | Facility | 2023 | 70 | 281 | $300,008 | $24,302 | 8.1% |
| 92250 | Photography of the retina | Office | 2023 | 280 | 532 | $242,060 | $16,114 | 6.7% |
| 92134 | Imaging of retina | Office | 2023 | 83 | 108 | $34,660 | $3,247 | 9.4% |
| 92133 | Imaging of optic nerve | Office | 2023 | 53 | 54 | $18,130 | $1,481 | 8.2% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 15 | 15 | $1,731 | $282.75 | 16.3% |
| 92014 | Established patient complete exam of visual system | Office | 2022 | 372 | 638 | $532,730 | $65,118 | 12.2% |
| 67028 | Injection of drug into eye | Facility | 2022 | 76 | 312 | $328,515 | $25,968 | 7.9% |
| 92134 | Imaging of retina | Office | 2022 | 566 | 755 | $222,725 | $23,812 | 10.7% |
| 92250 | Photography of the retina | Office | 2022 | 225 | 328 | $149,240 | $9,511 | 6.4% |
| 92133 | Imaging of optic nerve | Office | 2022 | 76 | 86 | $25,370 | $2,331 | 9.2% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2022 | 18 | 20 | $2,220 | $388.14 | 17.5% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2021 | 369 | 676 | $564,460 | $72,242 | 12.8% |
| 92134 | Diagnostic imaging of retina | Office | 2021 | 652 | 894 | $263,730 | $28,821 | 10.9% |
| 67028 | Injection of drug into eye | Facility | 2021 | 72 | 284 | $291,863 | $23,740 | 8.1% |
| 92250 | Photography of the retina | Office | 2021 | 191 | 257 | $116,935 | $8,689 | 7.4% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2021 | 132 | 139 | $41,005 | $3,686 | 9.0% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Facility | 2021 | 21 | 22 | $18,370 | $1,327 | 7.2% |
| 92201 | Extended examination of eye with drawing of retina | Office | 2021 | 14 | 14 | $1,554 | $286.13 | 18.4% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Office | 2020 | 359 | 610 | $509,350 | $61,119 | 12.0% |
| 92134 | Diagnostic imaging of retina | Office | 2020 | 517 | 790 | $221,090 | $25,054 | 11.3% |
| 67028 | Injection of drug into eye | Facility | 2020 | 71 | 268 | $269,238 | $24,182 | 9.0% |
| 92133 | Diagnostic imaging of optic nerve of eye | Office | 2020 | 198 | 215 | $54,825 | $5,843 | 10.7% |
| 92250 | Photography of the retina | Office | 2020 | 85 | 93 | $42,315 | $3,035 | 7.2% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Office | 2020 | 16 | 16 | $16,080 | $1,936 | 12.0% |
About Dr. David Sarraf, MD
Dr. David Sarraf, MD is a Ophthalmology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1477577591.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. David Sarraf, MD has received a total of $157,502 in payments from pharmaceutical and medical device companies, with $23,260 received in 2024. These payments were reported across 66 transactions from 15 companies. The most common payment nature is "Consulting Fee" ($122,656).
As a Medicare-enrolled provider, Sarraf has provided services to 4,931 Medicare beneficiaries, totaling 8,119 services with total Medicare billing of $501,530. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Los Angeles, CA
- Active Since 07/26/2006
- Last Updated 12/22/2010
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1477577591
Products in Payments
- AngioVue (Device) $58,000
- Lucentis (Biological) $23,777
- PAVBLU (Biological) $14,428
- Non-Covered Product (Drug) $10,886
- BEOVU (Drug) $6,988
- OPTICAL COHERENCE TOMOGRAPHY HOCT-1F (Device) $6,000
- Vabysmo (Drug) $2,750
- Solix (Device) $1,000
- EYLEA AFLIBERCEPT INJECTION (Biological) $360.58
- PLEX Elite 9000 (Device) $123.25
- EYLEA HD (Biological) $41.84
- XR (Device) $22.99
- OZURDEX (Drug) $16.55
- Cholbam (Drug) $0.83
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Los Angeles
Dr. Andrew Moshfeghi, Md, MD
Ophthalmology — Payments: $898,549
Ophthalmology $898,549
Dr. Barry Seibel, M.d, M.D
Ophthalmology — Payments: $893,403
Ophthalmology $893,403
Neda Shamie, M.d, M.D
Ophthalmology — Payments: $693,812
Ophthalmology $693,812
David Boyer, Md, MD
Ophthalmology — Payments: $514,544
Ophthalmology $514,544
David Hamilton, Od, OD
Ophthalmology — Payments: $477,856
Ophthalmology $477,856
Dr. Nicole Fram, Md, MD
Ophthalmology — Payments: $382,620
Ophthalmology $382,620